CCR 25 Post

AcademicCME appreciates your opinions to help assist us in the evaluation of the effectiveness of this activity and to identify your ongoing educational needs. Learners must complete this evaluation form to receive acknowledgement for completing this activity.

Name*

First NameLast Name

Email*

example@example.com

If PharmD, DOB

Date

If PharmD, NABP ID#

Private PracticeHospitalAcademicOther

How many patients do you typically see each month?

Please rate the extent to which this activity met the following objectives:

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Review the pathophysiology and mode of action of CAR T-cell therapy
Review the current clinical options, unmet needs, and emerging therapies for patients with severe, refractory systemic lupus erythematosus
Analyze the clinical trial data and clinical applications of CAR T-cell therapy to treat patients with severe, refractory SLE
Develop strategies to incorporate patient shared decision making when discussing CAR T-cell therapy for SLE

Please provide us with feedback regarding your experience at the activity:

Rows	Poor	Fair	Good	Very Good	Excellent
Overall Program
Content
Usefulness

Please rate the faculty on their overall teaching ability:

Rows	Poor	Fair	Good	Very Good	Excellent
Joan Merrill, MD

YesNo

If no, please explain:

YesNoN/A

What education would you like to see in the future?

Date

I participated in this activity and claim _______ credit(s).*

Attestation: This activity is certified for a maximum of 1.0 AMA PRA Category 1 Credits™.

POST-TEST QUESTIONNAIRE

EVALUATION FORM